NCT03454126View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

BIIB095

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (2)

LS2 9LH

Research Site, Leeds

NW10 7EW

Hammersmith Medicines Research, London

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY